Hepatitis Drugs and Vaccines: World Market 2013-2023
Your guide to sales outlooks and R&D for hepatitis treatments
Where are hepatitis medicines going? Visiongain's updated report predicts revenues there from 2013 to 2023. It also explains trends in that business and technology - with prospects and opportunities - to help your work.
In that study you gain sales forecasts at overall world market, submarket, product, and national level. See what's happening. Also discover what has most growth potential.
Read on, then, to explore that industry and see what its future market could be worth.
Forecasts to 2023 and other analyses show you commercial potentials
Besides revenue forecasting, our new work shows historical data, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and research developments (R&D). You also get 77 tables, 66 charts, and an interview.
Is finding data for anti-hepatitis products a challenge? Avoid falling behind. You can now stay ahead in knowledge, benefiting your research, analyses, and decisions. Also save time.
There you investigate the future of hepatitis medicine. You discover what's happening and see where the money lies. Finding that antiviral data just got easier.
Anyhow, the following sections show what you get in our new research and analysis.
Discover prospects for the world market and submarkets
Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts of four hepatitis treatment submarkets:
Also our study discusses what stimulates and restrains that market. That analysis helps you identify potential and find ways for your business to benefit.
You also find revenue predictions for brands.
See forecasts for 10 leading anti-hepatitis products
How will those antiviral brands perform to 2023 at world level? Our study forecasts individual revenues of 10 top products:
Our report also divides its overall world forecast into geographical regions.
What prospects for regions and countries?
Developments worldwide expand the hepatitis products market, especially rising demand for medicines in emerging countries. China, India, Russia, and Brazil underpin revenue growth.
In developed and developing countries, opportunities for pharmaceutical companies will occur from 2013 to 2023. See where and how.
Our analyses show you individual revenue forecasts to 2023 for 11 national markets:
Research and development - assess innovation, trends, and possibilities
What about R&D - pipelines for new drugs and vaccines? You assess trends there, including these:
For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing progress to help your work. See, then, what the future holds.
Prominent companies and 2017 market value
What happens next? From 2013, new treatments hold great potential for investment, technological advances and high revenues. Our report predicts the world market for anti-hepatitis drugs and vaccines will reach $15.25bn in 2017, and expand further to 2023.
Our work shows you what activities, technologies, and organisations there hold potential. Its analyses cover prominent companies, including these:
Nine ways Hepatitis Drugs and Vaccines: World Market 2013-2023 helps you
To sum up, our investigation gives you the following knowledge:
That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.
Assess the potential of those antiviral agents now, seeing what you can gain.
Hepatitis medicine - see commercial prospects from 2013 by ordering now
Our new study lets you find data, trends, opportunities, and sales predictions for hepatitis prevention and treatment. Avoid missing out - please order our report now.
Where are hepatitis medicines going? Visiongain's updated report predicts revenues there from 2013 to 2023. It also explains trends in that business and technology - with prospects and opportunities - to help your work.
In that study you gain sales forecasts at overall world market, submarket, product, and national level. See what's happening. Also discover what has most growth potential.
Read on, then, to explore that industry and see what its future market could be worth.
Forecasts to 2023 and other analyses show you commercial potentials
Besides revenue forecasting, our new work shows historical data, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and research developments (R&D). You also get 77 tables, 66 charts, and an interview.
Is finding data for anti-hepatitis products a challenge? Avoid falling behind. You can now stay ahead in knowledge, benefiting your research, analyses, and decisions. Also save time.
There you investigate the future of hepatitis medicine. You discover what's happening and see where the money lies. Finding that antiviral data just got easier.
Anyhow, the following sections show what you get in our new research and analysis.
Discover prospects for the world market and submarkets
Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts of four hepatitis treatment submarkets:
- Oral antivirals
- Interferons
- Vaccines
- Other agents.
Also our study discusses what stimulates and restrains that market. That analysis helps you identify potential and find ways for your business to benefit.
You also find revenue predictions for brands.
See forecasts for 10 leading anti-hepatitis products
How will those antiviral brands perform to 2023 at world level? Our study forecasts individual revenues of 10 top products:
- Baraclude
- Zeffix
- Hepsera
- Viread
- Tyzeka
- Engerix-B/Havrix/Twinrix/Fendrix
- Pegasys
- Incivek
- PegIntron
- Victrelis.
Our report also divides its overall world forecast into geographical regions.
What prospects for regions and countries?
Developments worldwide expand the hepatitis products market, especially rising demand for medicines in emerging countries. China, India, Russia, and Brazil underpin revenue growth.
In developed and developing countries, opportunities for pharmaceutical companies will occur from 2013 to 2023. See where and how.
Our analyses show you individual revenue forecasts to 2023 for 11 national markets:
- United States (US)
- Japan
- EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
- BRIC countries - Brazil, Russia, India, and China.
Research and development - assess innovation, trends, and possibilities
What about R&D - pipelines for new drugs and vaccines? You assess trends there, including these:
- Cyclophilin inhibition
- Protease inhibition
- All-oral agents
- Agents with potential roles in hep-C/HIV co-infection
- Nucleoside and non-nucleoside polymerase inhibition
- Therapeutic vaccines
- Combination regimens.
For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing progress to help your work. See, then, what the future holds.
Prominent companies and 2017 market value
What happens next? From 2013, new treatments hold great potential for investment, technological advances and high revenues. Our report predicts the world market for anti-hepatitis drugs and vaccines will reach $15.25bn in 2017, and expand further to 2023.
Our work shows you what activities, technologies, and organisations there hold potential. Its analyses cover prominent companies, including these:
- Roche
- GSK
- Bristol-Myers Squibb
- Merck & Co.
- Vertex Pharmaceuticals
- Gilead Sciences
- Novartis.
Nine ways Hepatitis Drugs and Vaccines: World Market 2013-2023 helps you
To sum up, our investigation gives you the following knowledge:
- Revenue to 2023 of the world market for anti-hepatitis products - discover that industry's overall sales potential
- Revenues to 2023 for 4 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and revenues
- Revenues to 2023 for 10 products - find sales outlooks for top brands, seeing how they can compete and succeed
- Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth
- Assessments of 11 companies - hear about participants' activities, capabilities, results, and outlooks
- Review of R&D - explore progress in research and development, finding technological and medical possibilities
- Competition and opportunities - investigate what shapes that market's future, including ways to develop business
- Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages
- Prospects for established competitors and firms seeking to enter that sector - explore needs, practices and outlooks for future success.
That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.
Assess the potential of those antiviral agents now, seeing what you can gain.
Hepatitis medicine - see commercial prospects from 2013 by ordering now
Our new study lets you find data, trends, opportunities, and sales predictions for hepatitis prevention and treatment. Avoid missing out - please order our report now.
1. EXECUTIVE SUMMARY
1.1 Hepatitis Treatments and Vaccines: World Market Overview
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
2. INTRODUCTION TO HEPATITIS AND ITS TREATMENTS
2.1 What is Hepatitis?
2.2 Diagnosing Hepatitis: The Asymptotic Nature of the Disease
2.3 How is Hepatitis Classified?
2.3.1 Hepatitis A
2.3.2 Hepatitis B
2.3.3 Hepatitis C
2.3.4 Hepatitis D
2.3.5 Hepatitis E
2.4 Risk Factors for Hepatitis
2.5 Incidence and Prevalence Patterns in Hepatitis
2.6 Hepatitis: Treatment and Prevention
2.6.1 Antivirals: Inhibiting Viral Replication
2.6.1.1 Reverse Transcriptase Inhibitors
2.6.1.2 Protease Inhibitors
2.6.2 Interferons: Dual Mode of Action
2.6.2.1 Combination Therapy: Treatment with Interferon and Antivirals
2.6.3 Vaccines: The Immunotherapeutic Approach
2.6.3.1 Hepatitis E Vaccine: Raising Hopes for an Overlooked Subtype
3. WORLD HEPATITIS TREATMENTS AND VACCINES MARKET, 2013-2023
3.1 The Hepatitis Treatments and Vaccines Market, 2012
3.1.1 The Hepatitis Treatment Market by Indication, 2012
3.2 The Hepatitis Treatments and Vaccines Market: Revenue Forecast, 2013-2023
3.2.1 Rising Awareness and Screening: Expanding Treatment Population
3.2.2 Generic Competition in the Hepatitis B Treatment Market
3.2.3 Biosimilar Interferons: A New Era in Hepatitis Treatment?
3.2.4 Direct-Acting Antivirals (DAAs): A Change in Therapeutic Landscape
3.3 Oral Antivirals Submarket, 2012
3.3.1 DAAs in Hepatitis B
3.3.2 DAAs in Hepatitis C
3.3.3 Oral Antivirals Submarket: Revenue Forecast, 2013-2023
3.3.4 Strong Developmental Pipeline to Drive Market Growth
3.3.5 All-Oral Treatments for Hepatitis C: Improving Tolerability
3.4 Interferons Submarket, 2012
3.4.1 Standard of Care for Hepatitis C
3.4.2 Drawbacks to Interferon Therapy
3.4.3 Declining Revenues 2008-2011
3.4.4 Interferons Submarket: Revenue Forecast, 2013-2023
3.4.5 Next Generation Interferons: A Potential Advance or Lateral Move?
3.5 Hepatitis Vaccines Submarket, 2012
3.5.1 GSK: A Dominant Global Player
3.5.2 Expanding Vaccination Programmes in Emerging Markets
3.5.3 Hepatitis Vaccines Submarket: Revenue Forecast, 2013-2023
3.6 Hepatitis Treatments and Vaccines: Submarket Shares 2012, 2018 and 2023
3.7 Hepatitis Treatment Market: Revenue Forecast by Indication, 2013-2023
4. LEADING NATIONAL HEPATITIS TREATMENTS AND VACCINES MARKETS, 2013-2023
4.1 Global Prevalence of Hepatitis, 2012
4.1.1 The Importance of Asia
4.2 Hepatitis Treatments and Vaccines Market: Regional Breakdown, 2012
4.3 Hepatitis Treatments and Vaccines Market: Regional Forecast, 2013-2023
4.4 The US
4.4.1 Population Movement and Hepatitis
4.4.2 Increased Screening towards Target Population
4.4.3 The US: Revenue Forecast, 2013-2023
4.5 Leading EU Markets for Hepatitis Treatments and Vaccines
4.5.1 Regional Prevalence
4.5.2 EU5 Market, 2012
4.5.3 EU5: Revenue Forecasts, 2013-2023
4.5.4 Italy: Revenue Forecast, 2013-2023
4.5.5 Spain: Revenue Forecast, 2013-2023
4.5.6 Germany: Revenue Forecast, 2013-2023
4.5.7 UK: Revenue Forecast, 2013-2023
4.5.8 France: Revenue Forecast, 2013-2023
4.6 Hepatitis in Asia
4.7 China
4.7.1 Increased Vaccination
4.7.2 Rising Middle Class
4.7.3 Hepatitis C Outbreaks
4.7.4 Domestic Drug and Vaccine Development
4.7.5 China: Revenue Forecast, 2013-2023
4.8 Japan
4.8.1 Hepatitis B and C in Japan
4.8.2 Japan: Revenue Forecast, 2013-2023
4.9 India
4.9.1 Low Awareness and Vaccination Rates
4.9.2 India: Revenue Forecast, 2013-2023
4.10 Russia
4.10.1 Low Treatment Rate and High Drug Costs Limiting Market
4.10.2 Russia: Revenue Forecast, 2013-2023
4.11 Brazil
4.11.1Current Disease Prevalence
4.11.2 Brazil: Revenue Forecast, 2013-2023
5. LEADING HEPATITIS THERAPIES: MARKET PROSPECTS TO 2023
5.1 Leading Hepatitis B Therapies, 2013-2023
5.2 Baraclude (Bristol-Myers Squibb)
5.2.1 Recent Revenue Analysis
5.2.2 Global Patent Challenges Will Hit Future Revenues
5.2.3 Baraclude: Revenue Forecast, 2013-2023
5.3 Zeffix (GSK)
5.3.1 Recent Revenue Analysis
5.3.2 Increasing Drug Resistance with Continued Use
5.3.3 Launch of Generic Versions Will Affect Drug Revenues
5.3.4 Zeffix: Revenue Forecast, 2013-2023
5.4 Hepsera (Gilead Sciences/GSK)
5.4.1 Recent Revenue Analysis
5.4.2 Patent Extension Approved Until 2016
5.4.3 Switching to Viread Will Limit Hepsera Revenues
5.4.4 Hepsera: Revenue Forecast, 2013-2023
5.5 Viread (Gilead Sciences)
5.5.1 Recent Revenue Analysis
5.5.2 GSK Alliance: Targeting Emerging Asian Markets
5.5.3 Competition with Viread Pro-drugs may Harm Drug Revenues
5.5.4 Viread: Revenue Forecast, 2013-2023
5.6 Tyzeka (Novartis)
5.6.1 Lack of Differentiation and Competition Affecting Market Share
5.6.2 Tyzeka: Revenue Forecast, 2013-2023
5.7 Leading Hepatitis B Vaccines, 2013-2023
5.8 Engerix-B/Havrix/Twinrix/Fendrix (GSK)
5.8.1 Recent Revenue Analysis
5.8.2 Demand and Supply in Emerging Markets
5.8.3 Pipeline Compounds Will Provide Strong Competition
5.8.4 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast, 2013-2023
5.9 Leading Hepatitis C Therapies, 2013-2023
5.10 Pegasys (Roche)
5.10.1 Recent Revenue Analysis
5.10.2 Label Expansions and Lifecycle Management Strategies
5.10.3 Pegasys: Revenue Forecast, 2013-2023
5.11 Incivek (Vertex Pharmaceuticals/J&J/Mitsubishi Tanabe)
5.11.1 Recent Revenue Analysis
5.11.2 Targeting Hep-C/HIV Co-Infected Patients
5.11.3 Incivek in Interferon-Free Regimens
5.11.4 Pipeline Competition May Affect Revenues
5.11.5 Incivek: Revenue Forecast, 2013-2023
5.12 PegIntron (Merck & Co.)
5.12.1 Recent Revenue Analysis
5.12.2 Competition from Interferon Biosimilars
5.12.3 Enhancing Drug Lifecycle
5.12.4 PegIntron: Revenue Forecast, 2013-2023
5.13 Victrelis (Merck & Co.)
5.13.1 Recent Revenue Analysis
5.13.2 Roche Collaboration
5.13.3 Product Differentiation
5.13.4 Victrelis: Revenue Forecast, 2013-2023
6. HEPATITIS TREATMENTS AND VACCINES MARKET: LEADING PIPELINE CANDIDATES
6.1 Leading Hepatitis C Pipeline Candidates, 2012
6.1.1 Alisporivir (Novartis/Debiopharm): Advanced Cyclophilin Inhibitor
6.1.2 BI 201335 (Boehringer Ingelheim): Fast-Tracked Protease Inhibitor
6.1.2.1 BI 207127 (Boehringer Ingelheim): First All-Oral Hep C Drug?
6.1.3 Daclatasvir (Bristol-Myers Squibb): Potential Role in Hep-C/HIV Co-Infection?
6.1.3.1 Asunaprevir (Bristol-Myers Squibb): Synergistic Effect with Daclatasvir
6.1.4 GS-7977 (Sofosbuvir; Gilead Sciences): Progression to Phase III
6.1.5 TMC435 (Tibotec Pharmaceuticals/Medivir): Next Generation Protease Inhibitor
6.1.5.1 TMC435 in All-Oral Regimens
6.1.6 Vaniprevir (Merck & Co.): Patent Security Till 2027
6.1.7 ABT-450 (Abbott Laboratories): Fast-Tracked Into Phase III
6.1.8 ACH-1625 (Achillion Pharmaceuticals): Playing Catch Up?
6.1.8.1 ACH-2684 (Achillion Pharmaceuticals)
6.1.8.2 ACH-2928 (Achillion Pharmaceuticals)
6.1.9 ChronVac-C (ChronTech Pharma/Inovio Pharmaceuticals): Therapeutic Vaccine in Phase II Trials
6.1.10 Danoprevir (Roche): Testing Out Combination Regimens
6.1.11 GI-5005 (GlobeImmune): Yeast-based Hep C Vaccine
6.1.12 IDX184 (Idenix Pharmaceuticals): Development Ceased
6.1.13 INX-189 (Bristol-Myers Squibb): Cardiovascular Effects May Halt Development
6.1.14 Locteron (Biolex): Controlled Release Formulation
6.1.15 Peginterferon Lambda-1a (Bristol-Myers Squibb): Improved Side Effect Profile
6.1.16 R7128 (Roche/Pharmasset): Broad Spectrum Treatment
6.1.17 SCY-635 (SCYNEXIS)
6.1.18 Setrobuvir (Roche): Fast-Tracked Polymerase Inhibitor
6.1.19 Tegobuvir (Gilead Sciences): Combination Therapy in Peginterferon-free Regimens
6.1.20 VX-222 (Vertex Pharmaceuticals): Landmark Interferon-Free Drug Regimen
6.2 Leading Hepatitis B Pipeline Candidates, 2012
6.2.1 Heplisav (Dynavax Technologies): Higher Seroprotection Levels
6.2.2 Rep 9AC' (REPLICor): Targeting Hb Surface Antigens
6.2.3 Myrcludex B (MYR): Dual Effect on Hepatitis B and D
6.2.4 AGX-1009 (Agenix): Tenofovir Prodrug Targeted towards China's Growing Hepatitis Population
7. LEADING COMPANIES IN THE HEPATITIS TREATMENTS AND VACCINES MARKET
7.1 Leading Market Players, 2012
7.2 Roche
7.2.1 Product Overview and Performance, 2012
7.2.2 Recent Developments: Partnership with Anadys
7.2.3 Hepatitis Pipeline
7.2.4 Future Outlook: Slowing Demand May Affect Market Dominance
7.3 GSK
7.3.1 Product Overview and Performance, 2012
7.3.2 Recent Developments: Increasing Focus on Novel Small Molecule Therapies
7.3.3 Hepatitis Pipeline: Polymerase Inhibitor in Phase II
7.3.4 Future Outlook: Dominance in Vaccines Unmatched
7.4 Bristol-Myers Squibb
7.4.1 Product Overview and Performance, 2012
7.4.2 Recent Developments: Strengthening Product Pipeline Through Acquisitions
7.4.2.1 Bristol-Myers Squibb Acquires Inhibitex
7.4.3 Hepatitis Pipeline: Strong Future Position in Hepatitis C
7.4.4 Future Outlook: Market Set For Intense Competition
7.5 Merck & Co.
7.5.1 Product Overview and Performance, 2012
7.5.2 Recent Developments: Discovering Combination Treatments Through Roche Partnership
7.5.3 Hepatitis Pipeline
7.5.4 Future Outlook: Company Pins Hopes on Victrelis and Launch of Pipeline Therapies
7.6 Vertex Pharmaceuticals
7.6.1 Product Overview and Performance, 2012
7.6.2 Recent Developments
7.6.3 Hepatitis Pipeline: Polymerase Inhibitors in Phase II Trials
7.6.4 Future Outlook: Company Hope Pipeline Will Maintain Market Position
7.7 Gilead Sciences
7.7.1 Product Overview and Performance, 2012
7.7.2 Recent Developments: Gilead Acquires Pharmasset
7.7.3 Hepatitis Pipeline: Strong and Diverse
7.7.4 Future Outlook: Strongest Pipeline Than Any Other Company
7.8 Novartis
7.8.1 Product Overview and Performance, 2012
7.8.2 Recent Developments: Company Partnerships/Collaborations to Strengthen Position
7.8.3 Hepatitis Pipeline: Improved Cyclophilin Inhibitor in Phase III Trials
7.8.4 Future Outlook
7.9 Leading Hepatitis Pipeline Companies, 2012
7.9.1 Abbott Laboratories: New Venture into Hepatitis
7.9.2 Achillion Pharmaceuticals: Next Target for Acquisition?
7.9.2.1 Achillion and Gilead
7.9.3 Boehringer Ingelheim: Focus on Protease/Polymerase Inhibitors
7.9.4 Idenix Pharmaceuticals: Pipeline Drug Receives Fast-Track Status
7.9.4.1 Idenix Pharmaceuticals: Outlook
8. HEPATITIS TREATMENTS AND VACCINES MARKET: INDUSTRY TRENDS, 2013-2023
8.1 Strengths and Weaknesses in the Hepatitis Treatments and Vaccines Market, 2013-2023
8.1.1 Resistance in Hepatitis B
8.1.2 Interferon Therapy Has Drawbacks
8.1.3 Genotype 1: A Common but Difficult to Treat Form of Hepatitis C
8.2 Opportunities and Threats in the Hepatitis Treatments and Vaccines Market, 2013-2023
8.2.1 Hepatitis Screening and Diagnosis
8.2.2 Raising Awareness and Overcoming Social Stigma
8.2.3 Personalised Therapy
8.2.4 HIV Co-Infection
8.2.5 Asia
8.3 STEP Analysis of the World Hepatitis Treatments and Vaccines Market, 2013-2023
8.3.1 Social Development
8.3.1.1 Social Implications in China
8.3.2 Technological Advances
8.3.3 Economic Pressures
8.3.4 Political Issues
8.4 Hepatitis B Vaccination
8.5 Limited Hepatitis B Pipeline
8.6 Hepatitis C Vaccines
8.7 Oral Direct-Acting Antivirals
8.7.1 Nucleoside and Non-Nucleoside Polymerase Inhibitors
8.7.2 Combining Protease and Polymerase Inhibitors
8.7.3 The Need for Ribavirin
8.7.4 Twelve Week Treatment Target
8.8 Pharmaceutical Investment in Hepatitis C
8.8.1 Licensing and Partnering Deals
8.8.2 Acquisitions in Hepatitis C
8.8.3 Future Targets for Collaboration or Acquisition
9. RESEARCH INTERVIEW
9.1 Interview with Mr Carl Stubbings, CBO, Benitec Pharma Ltd.
9.1.1 The Hepatitis C Treatment Market Landscape
9.1.2 TT-034: Cassette Vector for the Treatment of Hepatitis C
9.1.3 The Future Hepatitis Drug Market
10. CONCLUSIONS
10.1 State of the Hepatitis Treatments and Vaccines Market, 2012
10.2 Growth in the Hepatitis Treatments and Vaccines Market, 2013-2023
10.2.1 Rise of Direct-Acting Antivirals in Hepatitis C
10.2.2 Weak Pipeline for Hepatitis B
10.3 Asia as a Hepatitis Drug Market
1.1 Hepatitis Treatments and Vaccines: World Market Overview
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
2. INTRODUCTION TO HEPATITIS AND ITS TREATMENTS
2.1 What is Hepatitis?
2.2 Diagnosing Hepatitis: The Asymptotic Nature of the Disease
2.3 How is Hepatitis Classified?
2.3.1 Hepatitis A
2.3.2 Hepatitis B
2.3.3 Hepatitis C
2.3.4 Hepatitis D
2.3.5 Hepatitis E
2.4 Risk Factors for Hepatitis
2.5 Incidence and Prevalence Patterns in Hepatitis
2.6 Hepatitis: Treatment and Prevention
2.6.1 Antivirals: Inhibiting Viral Replication
2.6.1.1 Reverse Transcriptase Inhibitors
2.6.1.2 Protease Inhibitors
2.6.2 Interferons: Dual Mode of Action
2.6.2.1 Combination Therapy: Treatment with Interferon and Antivirals
2.6.3 Vaccines: The Immunotherapeutic Approach
2.6.3.1 Hepatitis E Vaccine: Raising Hopes for an Overlooked Subtype
3. WORLD HEPATITIS TREATMENTS AND VACCINES MARKET, 2013-2023
3.1 The Hepatitis Treatments and Vaccines Market, 2012
3.1.1 The Hepatitis Treatment Market by Indication, 2012
3.2 The Hepatitis Treatments and Vaccines Market: Revenue Forecast, 2013-2023
3.2.1 Rising Awareness and Screening: Expanding Treatment Population
3.2.2 Generic Competition in the Hepatitis B Treatment Market
3.2.3 Biosimilar Interferons: A New Era in Hepatitis Treatment?
3.2.4 Direct-Acting Antivirals (DAAs): A Change in Therapeutic Landscape
3.3 Oral Antivirals Submarket, 2012
3.3.1 DAAs in Hepatitis B
3.3.2 DAAs in Hepatitis C
3.3.3 Oral Antivirals Submarket: Revenue Forecast, 2013-2023
3.3.4 Strong Developmental Pipeline to Drive Market Growth
3.3.5 All-Oral Treatments for Hepatitis C: Improving Tolerability
3.4 Interferons Submarket, 2012
3.4.1 Standard of Care for Hepatitis C
3.4.2 Drawbacks to Interferon Therapy
3.4.3 Declining Revenues 2008-2011
3.4.4 Interferons Submarket: Revenue Forecast, 2013-2023
3.4.5 Next Generation Interferons: A Potential Advance or Lateral Move?
3.5 Hepatitis Vaccines Submarket, 2012
3.5.1 GSK: A Dominant Global Player
3.5.2 Expanding Vaccination Programmes in Emerging Markets
3.5.3 Hepatitis Vaccines Submarket: Revenue Forecast, 2013-2023
3.6 Hepatitis Treatments and Vaccines: Submarket Shares 2012, 2018 and 2023
3.7 Hepatitis Treatment Market: Revenue Forecast by Indication, 2013-2023
4. LEADING NATIONAL HEPATITIS TREATMENTS AND VACCINES MARKETS, 2013-2023
4.1 Global Prevalence of Hepatitis, 2012
4.1.1 The Importance of Asia
4.2 Hepatitis Treatments and Vaccines Market: Regional Breakdown, 2012
4.3 Hepatitis Treatments and Vaccines Market: Regional Forecast, 2013-2023
4.4 The US
4.4.1 Population Movement and Hepatitis
4.4.2 Increased Screening towards Target Population
4.4.3 The US: Revenue Forecast, 2013-2023
4.5 Leading EU Markets for Hepatitis Treatments and Vaccines
4.5.1 Regional Prevalence
4.5.2 EU5 Market, 2012
4.5.3 EU5: Revenue Forecasts, 2013-2023
4.5.4 Italy: Revenue Forecast, 2013-2023
4.5.5 Spain: Revenue Forecast, 2013-2023
4.5.6 Germany: Revenue Forecast, 2013-2023
4.5.7 UK: Revenue Forecast, 2013-2023
4.5.8 France: Revenue Forecast, 2013-2023
4.6 Hepatitis in Asia
4.7 China
4.7.1 Increased Vaccination
4.7.2 Rising Middle Class
4.7.3 Hepatitis C Outbreaks
4.7.4 Domestic Drug and Vaccine Development
4.7.5 China: Revenue Forecast, 2013-2023
4.8 Japan
4.8.1 Hepatitis B and C in Japan
4.8.2 Japan: Revenue Forecast, 2013-2023
4.9 India
4.9.1 Low Awareness and Vaccination Rates
4.9.2 India: Revenue Forecast, 2013-2023
4.10 Russia
4.10.1 Low Treatment Rate and High Drug Costs Limiting Market
4.10.2 Russia: Revenue Forecast, 2013-2023
4.11 Brazil
4.11.1Current Disease Prevalence
4.11.2 Brazil: Revenue Forecast, 2013-2023
5. LEADING HEPATITIS THERAPIES: MARKET PROSPECTS TO 2023
5.1 Leading Hepatitis B Therapies, 2013-2023
5.2 Baraclude (Bristol-Myers Squibb)
5.2.1 Recent Revenue Analysis
5.2.2 Global Patent Challenges Will Hit Future Revenues
5.2.3 Baraclude: Revenue Forecast, 2013-2023
5.3 Zeffix (GSK)
5.3.1 Recent Revenue Analysis
5.3.2 Increasing Drug Resistance with Continued Use
5.3.3 Launch of Generic Versions Will Affect Drug Revenues
5.3.4 Zeffix: Revenue Forecast, 2013-2023
5.4 Hepsera (Gilead Sciences/GSK)
5.4.1 Recent Revenue Analysis
5.4.2 Patent Extension Approved Until 2016
5.4.3 Switching to Viread Will Limit Hepsera Revenues
5.4.4 Hepsera: Revenue Forecast, 2013-2023
5.5 Viread (Gilead Sciences)
5.5.1 Recent Revenue Analysis
5.5.2 GSK Alliance: Targeting Emerging Asian Markets
5.5.3 Competition with Viread Pro-drugs may Harm Drug Revenues
5.5.4 Viread: Revenue Forecast, 2013-2023
5.6 Tyzeka (Novartis)
5.6.1 Lack of Differentiation and Competition Affecting Market Share
5.6.2 Tyzeka: Revenue Forecast, 2013-2023
5.7 Leading Hepatitis B Vaccines, 2013-2023
5.8 Engerix-B/Havrix/Twinrix/Fendrix (GSK)
5.8.1 Recent Revenue Analysis
5.8.2 Demand and Supply in Emerging Markets
5.8.3 Pipeline Compounds Will Provide Strong Competition
5.8.4 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast, 2013-2023
5.9 Leading Hepatitis C Therapies, 2013-2023
5.10 Pegasys (Roche)
5.10.1 Recent Revenue Analysis
5.10.2 Label Expansions and Lifecycle Management Strategies
5.10.3 Pegasys: Revenue Forecast, 2013-2023
5.11 Incivek (Vertex Pharmaceuticals/J&J/Mitsubishi Tanabe)
5.11.1 Recent Revenue Analysis
5.11.2 Targeting Hep-C/HIV Co-Infected Patients
5.11.3 Incivek in Interferon-Free Regimens
5.11.4 Pipeline Competition May Affect Revenues
5.11.5 Incivek: Revenue Forecast, 2013-2023
5.12 PegIntron (Merck & Co.)
5.12.1 Recent Revenue Analysis
5.12.2 Competition from Interferon Biosimilars
5.12.3 Enhancing Drug Lifecycle
5.12.4 PegIntron: Revenue Forecast, 2013-2023
5.13 Victrelis (Merck & Co.)
5.13.1 Recent Revenue Analysis
5.13.2 Roche Collaboration
5.13.3 Product Differentiation
5.13.4 Victrelis: Revenue Forecast, 2013-2023
6. HEPATITIS TREATMENTS AND VACCINES MARKET: LEADING PIPELINE CANDIDATES
6.1 Leading Hepatitis C Pipeline Candidates, 2012
6.1.1 Alisporivir (Novartis/Debiopharm): Advanced Cyclophilin Inhibitor
6.1.2 BI 201335 (Boehringer Ingelheim): Fast-Tracked Protease Inhibitor
6.1.2.1 BI 207127 (Boehringer Ingelheim): First All-Oral Hep C Drug?
6.1.3 Daclatasvir (Bristol-Myers Squibb): Potential Role in Hep-C/HIV Co-Infection?
6.1.3.1 Asunaprevir (Bristol-Myers Squibb): Synergistic Effect with Daclatasvir
6.1.4 GS-7977 (Sofosbuvir; Gilead Sciences): Progression to Phase III
6.1.5 TMC435 (Tibotec Pharmaceuticals/Medivir): Next Generation Protease Inhibitor
6.1.5.1 TMC435 in All-Oral Regimens
6.1.6 Vaniprevir (Merck & Co.): Patent Security Till 2027
6.1.7 ABT-450 (Abbott Laboratories): Fast-Tracked Into Phase III
6.1.8 ACH-1625 (Achillion Pharmaceuticals): Playing Catch Up?
6.1.8.1 ACH-2684 (Achillion Pharmaceuticals)
6.1.8.2 ACH-2928 (Achillion Pharmaceuticals)
6.1.9 ChronVac-C (ChronTech Pharma/Inovio Pharmaceuticals): Therapeutic Vaccine in Phase II Trials
6.1.10 Danoprevir (Roche): Testing Out Combination Regimens
6.1.11 GI-5005 (GlobeImmune): Yeast-based Hep C Vaccine
6.1.12 IDX184 (Idenix Pharmaceuticals): Development Ceased
6.1.13 INX-189 (Bristol-Myers Squibb): Cardiovascular Effects May Halt Development
6.1.14 Locteron (Biolex): Controlled Release Formulation
6.1.15 Peginterferon Lambda-1a (Bristol-Myers Squibb): Improved Side Effect Profile
6.1.16 R7128 (Roche/Pharmasset): Broad Spectrum Treatment
6.1.17 SCY-635 (SCYNEXIS)
6.1.18 Setrobuvir (Roche): Fast-Tracked Polymerase Inhibitor
6.1.19 Tegobuvir (Gilead Sciences): Combination Therapy in Peginterferon-free Regimens
6.1.20 VX-222 (Vertex Pharmaceuticals): Landmark Interferon-Free Drug Regimen
6.2 Leading Hepatitis B Pipeline Candidates, 2012
6.2.1 Heplisav (Dynavax Technologies): Higher Seroprotection Levels
6.2.2 Rep 9AC' (REPLICor): Targeting Hb Surface Antigens
6.2.3 Myrcludex B (MYR): Dual Effect on Hepatitis B and D
6.2.4 AGX-1009 (Agenix): Tenofovir Prodrug Targeted towards China's Growing Hepatitis Population
7. LEADING COMPANIES IN THE HEPATITIS TREATMENTS AND VACCINES MARKET
7.1 Leading Market Players, 2012
7.2 Roche
7.2.1 Product Overview and Performance, 2012
7.2.2 Recent Developments: Partnership with Anadys
7.2.3 Hepatitis Pipeline
7.2.4 Future Outlook: Slowing Demand May Affect Market Dominance
7.3 GSK
7.3.1 Product Overview and Performance, 2012
7.3.2 Recent Developments: Increasing Focus on Novel Small Molecule Therapies
7.3.3 Hepatitis Pipeline: Polymerase Inhibitor in Phase II
7.3.4 Future Outlook: Dominance in Vaccines Unmatched
7.4 Bristol-Myers Squibb
7.4.1 Product Overview and Performance, 2012
7.4.2 Recent Developments: Strengthening Product Pipeline Through Acquisitions
7.4.2.1 Bristol-Myers Squibb Acquires Inhibitex
7.4.3 Hepatitis Pipeline: Strong Future Position in Hepatitis C
7.4.4 Future Outlook: Market Set For Intense Competition
7.5 Merck & Co.
7.5.1 Product Overview and Performance, 2012
7.5.2 Recent Developments: Discovering Combination Treatments Through Roche Partnership
7.5.3 Hepatitis Pipeline
7.5.4 Future Outlook: Company Pins Hopes on Victrelis and Launch of Pipeline Therapies
7.6 Vertex Pharmaceuticals
7.6.1 Product Overview and Performance, 2012
7.6.2 Recent Developments
7.6.3 Hepatitis Pipeline: Polymerase Inhibitors in Phase II Trials
7.6.4 Future Outlook: Company Hope Pipeline Will Maintain Market Position
7.7 Gilead Sciences
7.7.1 Product Overview and Performance, 2012
7.7.2 Recent Developments: Gilead Acquires Pharmasset
7.7.3 Hepatitis Pipeline: Strong and Diverse
7.7.4 Future Outlook: Strongest Pipeline Than Any Other Company
7.8 Novartis
7.8.1 Product Overview and Performance, 2012
7.8.2 Recent Developments: Company Partnerships/Collaborations to Strengthen Position
7.8.3 Hepatitis Pipeline: Improved Cyclophilin Inhibitor in Phase III Trials
7.8.4 Future Outlook
7.9 Leading Hepatitis Pipeline Companies, 2012
7.9.1 Abbott Laboratories: New Venture into Hepatitis
7.9.2 Achillion Pharmaceuticals: Next Target for Acquisition?
7.9.2.1 Achillion and Gilead
7.9.3 Boehringer Ingelheim: Focus on Protease/Polymerase Inhibitors
7.9.4 Idenix Pharmaceuticals: Pipeline Drug Receives Fast-Track Status
7.9.4.1 Idenix Pharmaceuticals: Outlook
8. HEPATITIS TREATMENTS AND VACCINES MARKET: INDUSTRY TRENDS, 2013-2023
8.1 Strengths and Weaknesses in the Hepatitis Treatments and Vaccines Market, 2013-2023
8.1.1 Resistance in Hepatitis B
8.1.2 Interferon Therapy Has Drawbacks
8.1.3 Genotype 1: A Common but Difficult to Treat Form of Hepatitis C
8.2 Opportunities and Threats in the Hepatitis Treatments and Vaccines Market, 2013-2023
8.2.1 Hepatitis Screening and Diagnosis
8.2.2 Raising Awareness and Overcoming Social Stigma
8.2.3 Personalised Therapy
8.2.4 HIV Co-Infection
8.2.5 Asia
8.3 STEP Analysis of the World Hepatitis Treatments and Vaccines Market, 2013-2023
8.3.1 Social Development
8.3.1.1 Social Implications in China
8.3.2 Technological Advances
8.3.3 Economic Pressures
8.3.4 Political Issues
8.4 Hepatitis B Vaccination
8.5 Limited Hepatitis B Pipeline
8.6 Hepatitis C Vaccines
8.7 Oral Direct-Acting Antivirals
8.7.1 Nucleoside and Non-Nucleoside Polymerase Inhibitors
8.7.2 Combining Protease and Polymerase Inhibitors
8.7.3 The Need for Ribavirin
8.7.4 Twelve Week Treatment Target
8.8 Pharmaceutical Investment in Hepatitis C
8.8.1 Licensing and Partnering Deals
8.8.2 Acquisitions in Hepatitis C
8.8.3 Future Targets for Collaboration or Acquisition
9. RESEARCH INTERVIEW
9.1 Interview with Mr Carl Stubbings, CBO, Benitec Pharma Ltd.
9.1.1 The Hepatitis C Treatment Market Landscape
9.1.2 TT-034: Cassette Vector for the Treatment of Hepatitis C
9.1.3 The Future Hepatitis Drug Market
10. CONCLUSIONS
10.1 State of the Hepatitis Treatments and Vaccines Market, 2012
10.2 Growth in the Hepatitis Treatments and Vaccines Market, 2013-2023
10.2.1 Rise of Direct-Acting Antivirals in Hepatitis C
10.2.2 Weak Pipeline for Hepatitis B
10.3 Asia as a Hepatitis Drug Market
LIST OF TABLES
Table 1.1 Currency Exchange Rates
Table 1.2 Abbreviations and Acronyms Used in the Report
Table 2.1 Hepatitis Subtypes: An Overview
Table 2.2 Polymerase Inhibitors Approved for Hepatitis B in the US and EU, 2012
Table 3.1 Hepatitis Treatments and Vaccines: Revenue ($bn) and Market Share (%) by Sector, 2012
Table 3.2 Hepatitis Treatment Market: Revenue ($bn) and Market Share (%) by Indication, 2012
Table 3.3 Hepatitis Treatments and Vaccines: Overall Market and Revenue Forecasts ($bn) by Sector, 2013-2023
Table 3.4 Selected Biosimilar Interferon Alpha Therapies Approved in Emerging Markets, 2013
Table 3.5 Oral Antivirals Submarket: Revenue ($bn) and Market Share (%) by Drug, 2012
Table 3.6 Oral Antivirals Submarket: Revenue Forecast ($bn), 2013-2023
Table 3.7 Interferons Submarket: Revenue ($bn) and Market Share (%) by Drug, 2012
Table 3.8 Interferons Submarket: Revenue Forecast ($bn), 2013-2023
Table 3.9 Vaccines Submarket: Revenue ($bn) and Market Share (%) by Drug, 2012
Table 3.10 Vaccines Submarket: Revenue Forecast ($bn), 2013-2023
Table 3.11 Hepatitis Treatments and Vaccines: Revenue ($bn) and Market Share (%) by Sector in 2012, 2018 and 2023
Table 3.12 Hepatitis Treatment Market: Overall Market and Revenue Forecasts ($bn) by Indication, 2013-2023
Table 4.1 Chronic Hepatitis B & C: Global Prevalence (millions) by Region, 2012
Table 4.2 Hepatitis Treatments and Vaccines: Revenue ($bn) and Market Share (%) by Region, 2012
Table 4.3 Hepatitis Treatments and Vaccines: Overall Market and Revenue Forecasts ($bn) by Region, 2013-2023
Table 4.4 US Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.5 EU5 Hepatitis Treatments and Vaccines: Revenue ($bn), EU5 Market Share (%) and Global Market Share (%) by Country, 2012
Table 4.6 EU5 Hepatitis Treatments and Vaccines Market: Revenue Forecasts ($bn) by Country, 2013-2023
Table 4.7 Italian Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.8 Spanish Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.9 German Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.10 UK Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.11 French Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.12 Chinese Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.13 Japanese Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.14 Indian Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.15 Russian Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.16 Brazilian Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 5.1 Baraclude: Key Facts, 2012
Table 5.2 Baraclude: Revenue ($bn) by Region, 2010-2012
Table 5.3 Baraclude: Revenue Forecast ($bn), 2013-2023
Table 5.4 Zeffix: Key Facts, 2012
Table 5.5 Zeffix: Revenue ($bn) by Region, 2011-2012
Table 5.6 Zeffix: Revenue Forecast ($bn), 2013-2023
Table 5.7 Hepsera: Key Facts, 2012
Table 5.8 Hepsera: Revenue ($bn) by Company, 2010-2012
Table 5.9 Hepsera: Revenue Forecast ($bn), 2013-2023
Table 5.10 Viread: Key Facts, 2012
Table 5.11 Viread: Revenue Forecast ($bn), 2013-2023
Table 5.12 Tyzeka: Key Facts, 2012
Table 5.13 Tyzeka: Revenue Forecast ($bn), 2013-2023
Table 5.14 GSK's Hepatitis Vaccines: Key Facts, 2012
Table 5.15 Engerix-B/Havrix/Twinrix/Fendrix: Revenue ($bn) and Market Share (%) by Region, 2012
Table 5.16 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast ($bn), 2013-2023
Table 5.17 Pegasys: Key Facts, 2012
Table 5.18 Pegasys: Revenue Forecast ($bn), 2013-2023
Table 5.19 Incivek: Key Facts, 2012
Table 5.20 Incivek: Revenue ($bn) and Market Share (%) by Region, 2012
Table 5.21 Incivek: Revenue Forecast ($bn), 2013-2023
Table 5.22 PegIntron: Key Facts, 2012
Table 5.23 PegIntron: Revenue Forecast ($bn), 2013-2023
Table 5.24 Victrelis: Key Facts, 2012
Table 5.25 Victrelis: Revenue Forecast ($bn), 2013-2023
Table 6.1 Selected Hepatitis C Pipeline Candidates in Phase II & III, 2012
Table 6.2 Alisporivir: Phase III Trials, 2012
Table 6.3 Selected Hepatitis B Pipeline Candidates in Clinical Trials, 2012
Table 7.1 Hepatitis Treatments and Vaccines: Revenue ($bn) and Market Share (%) by Company, 2012
Table 7.2 Roche: Hepatitis Pipeline, 2012
Table 7.3 Pegasys: Revenue ($bn) and Market Share (%) in 2012, 2018 and 2023
Table 7.4 GSK Pharmaceuticals: Revenue ($bn) and Market Share (%) by Therapeutic Area, 2012
Table 7.5 Bristol-Myers Squibb: Hepatitis Pipeline, 2012
Table 7.6 Merck & Co: Revenue ($bn) and Market Share (%) by Therapeutic Area, 2012
Table 7.7 Telaprevir: Revenue ($bn) by Trade Name, 2012
Table 7.8 Gilead Sciences: Revenue ($bn) and Market Share (%) by Therapeutic Area, 2012
Table 7.9 Gilead Sciences: Hepatitis Pipeline, 2012
Table 7.10 Achillion Pharmaceuticals: Hepatitis Pipeline, 2012
Table 7.11 Idenix Pharmaceuticals: Hepatitis Pipeline, 2012
Table 8.1 Hepatitis Treatments and Vaccines Market: Strengths and Weaknesses, 2013
Table 8.2 Hepatitis Treatments and Vaccines Market: Opportunities and Threats, 2013-2023
Table 8.3 Liver Cancer: Global Deaths (per 100,000) by Region, 2008
Table 8.4 Selected Pipeline Drugs Granted Fast Track Status, 2011-2012
Table 8.5 Selected All-Oral Hepatitis C Regimens in Development, 2012
Table 8.6 Market Capitalisation of Selected Hepatitis Drug Developers, 2012
Table 10.1 Hepatitis Treatments and Vaccines: Revenue ($bn) by Drug & Sector in 2012, 2018 & 2023
Table 10.2 Leading Hepatitis Treatments: Patent Expiries & Peak Revenues ($bn)
Table 1.1 Currency Exchange Rates
Table 1.2 Abbreviations and Acronyms Used in the Report
Table 2.1 Hepatitis Subtypes: An Overview
Table 2.2 Polymerase Inhibitors Approved for Hepatitis B in the US and EU, 2012
Table 3.1 Hepatitis Treatments and Vaccines: Revenue ($bn) and Market Share (%) by Sector, 2012
Table 3.2 Hepatitis Treatment Market: Revenue ($bn) and Market Share (%) by Indication, 2012
Table 3.3 Hepatitis Treatments and Vaccines: Overall Market and Revenue Forecasts ($bn) by Sector, 2013-2023
Table 3.4 Selected Biosimilar Interferon Alpha Therapies Approved in Emerging Markets, 2013
Table 3.5 Oral Antivirals Submarket: Revenue ($bn) and Market Share (%) by Drug, 2012
Table 3.6 Oral Antivirals Submarket: Revenue Forecast ($bn), 2013-2023
Table 3.7 Interferons Submarket: Revenue ($bn) and Market Share (%) by Drug, 2012
Table 3.8 Interferons Submarket: Revenue Forecast ($bn), 2013-2023
Table 3.9 Vaccines Submarket: Revenue ($bn) and Market Share (%) by Drug, 2012
Table 3.10 Vaccines Submarket: Revenue Forecast ($bn), 2013-2023
Table 3.11 Hepatitis Treatments and Vaccines: Revenue ($bn) and Market Share (%) by Sector in 2012, 2018 and 2023
Table 3.12 Hepatitis Treatment Market: Overall Market and Revenue Forecasts ($bn) by Indication, 2013-2023
Table 4.1 Chronic Hepatitis B & C: Global Prevalence (millions) by Region, 2012
Table 4.2 Hepatitis Treatments and Vaccines: Revenue ($bn) and Market Share (%) by Region, 2012
Table 4.3 Hepatitis Treatments and Vaccines: Overall Market and Revenue Forecasts ($bn) by Region, 2013-2023
Table 4.4 US Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.5 EU5 Hepatitis Treatments and Vaccines: Revenue ($bn), EU5 Market Share (%) and Global Market Share (%) by Country, 2012
Table 4.6 EU5 Hepatitis Treatments and Vaccines Market: Revenue Forecasts ($bn) by Country, 2013-2023
Table 4.7 Italian Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.8 Spanish Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.9 German Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.10 UK Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.11 French Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.12 Chinese Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.13 Japanese Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.14 Indian Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.15 Russian Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 4.16 Brazilian Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
Table 5.1 Baraclude: Key Facts, 2012
Table 5.2 Baraclude: Revenue ($bn) by Region, 2010-2012
Table 5.3 Baraclude: Revenue Forecast ($bn), 2013-2023
Table 5.4 Zeffix: Key Facts, 2012
Table 5.5 Zeffix: Revenue ($bn) by Region, 2011-2012
Table 5.6 Zeffix: Revenue Forecast ($bn), 2013-2023
Table 5.7 Hepsera: Key Facts, 2012
Table 5.8 Hepsera: Revenue ($bn) by Company, 2010-2012
Table 5.9 Hepsera: Revenue Forecast ($bn), 2013-2023
Table 5.10 Viread: Key Facts, 2012
Table 5.11 Viread: Revenue Forecast ($bn), 2013-2023
Table 5.12 Tyzeka: Key Facts, 2012
Table 5.13 Tyzeka: Revenue Forecast ($bn), 2013-2023
Table 5.14 GSK's Hepatitis Vaccines: Key Facts, 2012
Table 5.15 Engerix-B/Havrix/Twinrix/Fendrix: Revenue ($bn) and Market Share (%) by Region, 2012
Table 5.16 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast ($bn), 2013-2023
Table 5.17 Pegasys: Key Facts, 2012
Table 5.18 Pegasys: Revenue Forecast ($bn), 2013-2023
Table 5.19 Incivek: Key Facts, 2012
Table 5.20 Incivek: Revenue ($bn) and Market Share (%) by Region, 2012
Table 5.21 Incivek: Revenue Forecast ($bn), 2013-2023
Table 5.22 PegIntron: Key Facts, 2012
Table 5.23 PegIntron: Revenue Forecast ($bn), 2013-2023
Table 5.24 Victrelis: Key Facts, 2012
Table 5.25 Victrelis: Revenue Forecast ($bn), 2013-2023
Table 6.1 Selected Hepatitis C Pipeline Candidates in Phase II & III, 2012
Table 6.2 Alisporivir: Phase III Trials, 2012
Table 6.3 Selected Hepatitis B Pipeline Candidates in Clinical Trials, 2012
Table 7.1 Hepatitis Treatments and Vaccines: Revenue ($bn) and Market Share (%) by Company, 2012
Table 7.2 Roche: Hepatitis Pipeline, 2012
Table 7.3 Pegasys: Revenue ($bn) and Market Share (%) in 2012, 2018 and 2023
Table 7.4 GSK Pharmaceuticals: Revenue ($bn) and Market Share (%) by Therapeutic Area, 2012
Table 7.5 Bristol-Myers Squibb: Hepatitis Pipeline, 2012
Table 7.6 Merck & Co: Revenue ($bn) and Market Share (%) by Therapeutic Area, 2012
Table 7.7 Telaprevir: Revenue ($bn) by Trade Name, 2012
Table 7.8 Gilead Sciences: Revenue ($bn) and Market Share (%) by Therapeutic Area, 2012
Table 7.9 Gilead Sciences: Hepatitis Pipeline, 2012
Table 7.10 Achillion Pharmaceuticals: Hepatitis Pipeline, 2012
Table 7.11 Idenix Pharmaceuticals: Hepatitis Pipeline, 2012
Table 8.1 Hepatitis Treatments and Vaccines Market: Strengths and Weaknesses, 2013
Table 8.2 Hepatitis Treatments and Vaccines Market: Opportunities and Threats, 2013-2023
Table 8.3 Liver Cancer: Global Deaths (per 100,000) by Region, 2008
Table 8.4 Selected Pipeline Drugs Granted Fast Track Status, 2011-2012
Table 8.5 Selected All-Oral Hepatitis C Regimens in Development, 2012
Table 8.6 Market Capitalisation of Selected Hepatitis Drug Developers, 2012
Table 10.1 Hepatitis Treatments and Vaccines: Revenue ($bn) by Drug & Sector in 2012, 2018 & 2023
Table 10.2 Leading Hepatitis Treatments: Patent Expiries & Peak Revenues ($bn)
Lack of Differentiation and Competition Affecting Market Share
The oral polymerase inhibitor sector of the hepatitis B market is highly competitive, with five leading brands available in major markets worldwide. Tyzeka was the fourth of these to be approved and, it currently struggles to compete in terms of market share. This is reportedly owingto its resistance profile, which mirrors that of other products that have been available on the market for longer, meaning there is little clear differentiation from other drugs. Additionally, its resistance profile means that under current regulatory guidelines, Tyzeka is not recommended as a first-line therapy for hepatitis B. However, unlike Viread, Tyzeka is available in China, having been approved there in March 2007.
Tyzeka: Revenue Forecast, 2013-2023
In spite of the drug’s resistance, visiongain anticipates growth in Tyzeka’s revenue for the early forecast period of this report, due to increased uptake in all markets worldwide. However, the lack of competitiveness in comparison to other oral antivirals, particularly those approved around the same time as Tyzeka, mean that it will struggle to achieve high revenues. The resistance profile of Tyzeka is weaker than that for Baraclude and Viread, visiongain notes. Therefore the rate of revenue growth will fall towards patent expiry for the drug in 2020. Peak revenue will be $0.11bn in 2020. Between 2012 and 2018, Tyzeka’s revenue will grow with a CAGR of 9.9%. The continued demand for oral antivirals in treating hepatitis B, given the lack of novel drugs in the pipeline, will drive this growth. By 2023, however, revenue will have fallen to $0.06bn, visiongain predicts.
